A new study published in April 2026 by scientists from the University of Barcelona presents a promising approach to the treatment of one of the most common liver diseases\u2014metabolic dysfunction-associated steatotic liver disease. This condition affects millions of people worldwide and often progresses without symptoms, but over time it can lead to serious complications, including severe liver damage and an increased risk of cardiovascular diseases.<\/p>\n
The main novelty of the study lies in the combined use of two already existing drugs\u2014pemafibrate and telmisartan. In experimental models, the researchers found that this drug combination significantly reduces fat accumulation in the liver. Even more interestingly, the use of these medications together at low doses proved to be as effective as using each drug separately at higher doses. This finding is particularly important because it may reduce the risk of side effects and make treatment safer.<\/p>\n
In addition to improving liver function, the study also showed beneficial effects on the cardiovascular system. Since this disease is often associated with increased cardiovascular risk, such a dual effect represents a new strategic direction in treatment. However, the scientists emphasize that despite the encouraging results, the research is still at a preclinical stage, and further studies in humans are necessary to confirm its effectiveness and safety in clinical practice.<\/p>\n
It is also important that the study is based on drug repurposing, meaning the use of already existing medications for new therapeutic purposes. This approach can significantly accelerate the development of new treatments, as the safety profiles of such drugs are already partially known. As a result, this discovery may become an important step toward improving the treatment of liver diseases and could gain real clinical relevance in the future.<\/p>\n